http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Association of 20 potential ATP2B1‐interacting genes with blood pressure in Koreans
Kyung‐Won Hong,Hyun‐Seok Jin,Ji‐Eun Lim,Bermseok Oh 한국유전학회 2011 Genes & Genomics Vol.33 No.3
Plasma membrane calcium‐transporting ATPase 1 (ATP2B1)is associated significantly with blood pressure in Caucasians and Asians. ATP2B1 regulates calcium homeostasis and belongs to the P‐type calcium pump family; several studies have identified diverse proteins that bind to ATP2B1. We hypothesized that ATP2B1 regulates blood pressure through ATP2B1‐interacting genes. To this end, 20 potential ATP2B1‐interacting genes were selected, 197 SNPs of which were analyzed for their association of systolic and diastolic blood pressure. These 20 genes were categorized into 2 groups: ATP2B1‐binding genes and ATP2B1‐cleaving calpain family members. Three ATP2B1‐binding genes (CALM1, NOS1, and PDLIM1)were associated with blood pressure, and a SNP in CALM1(rs2401887) generated the strongest association signal (beta=‐3.60±0.92, p=8.9×10^(‐5) for systolic blood pressure and beta=‐1.40±0.62, p=0.02 for diastolic blood pressure). Of the calpain family members, 3 genes (CAPN6, CAPN9, and CAPN10)were associated with blood pressure, and the CAPN10 SNP rs4676348 yielded the strongest association signal (beta=‐0.88±0.27, p=0.001 for systolic blood pressure and beta=‐0.58±0.18, p=0.015 for diastolic blood pressure). Further, the interaction of CALM1 to ATP2B1 was examined using the blood pressure of individuals who carried both variants of CALM1and ATP2B1 genes. Similarly the interaction of CAPN10 to ATP2B1 was also examined. The CALM1 variant (rs2401887)and CAPN10 variants (rs4676348) appear to decrease blood pressure further in addition to the decrease by the variant (rs17249754) of ATP2B1, which suggests that ATP2B1 might regulate blood pressure through the ATP2B1‐interacting genes CALM1 and CAPN10.
진심통(眞心痛)에 관(關)한 문헌적(文獻的) 고찰(考察)
전찬용,조기호,이원철,김영석,배형섭,이경섭,구본홍,Jun, Chan-Yong,Jo, Ki-Ho,Lee, Won-Chol,金永錫, Yong-Seok,Bhae, Hyung-Sup,Lee, Kyung-Sup,Goo, Bon-Hong 대한한방내과학회 1990 大韓韓方內科學會誌 Vol.11 No.1
The true heartache is a condition of severe heartache corresponding to angina pectoris, as recorded from Hwang Jae Nai Kyung. According to the literatural study of true heartache, some results can be acquired, such as follows. 1. The site of the true Heartache, can be divided into two categories, first, its superficial and conscious area is the chest as same as the other heartache. But its inner lesion is the Heart-Meridian as others occupied at the Pericardium-Meridian in stead of the Heart-Meridian. 2. The etiological classification of true heartache, are Cold-evil, Heat-evil, Wind-evil, Blood stasis etc. But its major factor is Cold-evil, more than anything else. 3. The symptomatic signs of true heartache, consist of cyanotic change from hands and feet to phalanges; severe heartache pale complexion with cold breathing and its extreme state can manifestate unceased sweating called as Yang exhaustion.
Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma
Hong, Eun Kyoung,Choi, Seung Hong,Shin, Dong Jae,Jo, Sang Won,Yoo, Roh-Eul,Kang, Koung Mi,Yun, Tae Jin,Kim, Ji-Hoon,Sohn, Chul-Ho,Park, Sung-Hye,Won, Jae-Kyung,Kim, Tae Min,Park, Chul-Kee,Kim, Il Han Springer-Verlag 2018 EUROPEAN RADIOLOGY Vol.28 No.10
The Protective Effect of Resveratrol on Dimethylnitrosamine-Induced Liver Fibrosis in Rats
Hong, Sang-Won,Jung, Kyung-Hee,Zheng, Hong-Mei,Lee, Hee-Seung,Suh, Jun-Kyu,Park, In-Suh,Lee, Don-Haeng,Hong, Soon-Sun 대한약학회 2010 Archives of Pharmacal Research Vol.33 No.4
Oxidative stress in liver injury is a major pathogenetic factor in progress of liver fibrosis. Resveratrol, a representative antioxidant derived from grapes, has been reported to show widespread pharmacological properties. In this study, we investigated the protective effects of resveratrol on dimethylnitrosamine (DMN)-induced liver fibrosis in rats. Rats were treated with resveratrol daily by oral gavage for seven days after a single intraperitoneal injection of DMN (40 mg/kg). Resveratrol remarkably recovered body and liver weight loss due to DMNinduced liver fibrosis. Liver histology showed that resveratrol alleviated the infiltration of inflammatory cells and fibrosis of liver tissue. Resveratrol decreased the level of malondialdehyde and increased the levels of glutathione peroxidase and superoxide dismutase. Also, resveratrol significantly inhibited the mRNA expression of inflammatory mediators including inducible nitric oxide, tumor necrosis factor-alpha and interleukin-1beta. In addition, resveratrol showed not only reduced mRNA expression of fibrosis-related genes such as transforming growth factor beta 1, collagen type I, and alpha-smooth muscle actin, but also a significant decrease of hydroxyproline in rats with DMN-induced liver fibrosis. Our results suggest that resveratrol could be used to treat liver injury and fibrosis and be useful in preventing the development of liver fibrosis and cirrhosis.
Hong Seok Kim,이영균,Samuel Jaeyoon Won,Se Jin Park,Jung-Wee Park,Kyung-Hoi Koo 대한의학회 2022 Journal of Korean medical science Vol.37 No.2
Background: At the end of 2014, we implemented an online video to inform patients of the entire process from admission to rehabilitation after total hip arthroplasty (THA). In this study, we investigated the effectiveness of online video instruction in THA patients. Methods: Electronic medical records of 184 patients undergoing THA in 2014 (pre-video group) and 182 patients in 2015 (post-video group) were reviewed. We compared 1) the time to start wheelchair ambulation, 2) walker or crutch ambulation, 3) the length of hospital stay, 4) postoperative satisfaction using visual analogue scale (0–10 points), and 5) modified Harris Hip Score (mHHS) at postoperative 6 weeks. Results: In the post-video group, the time to start wheelchair ambulation (1.8 ± 0.6 vs. 2.4 ± 3.2 days, P = 0.021) and walker/crutch ambulation were faster (2.9 ± 1.2 vs. 3.8 ± 1.0 days, P = 0.016), and the hospital stay was shorter (8.2 ± 4.7 vs. 9.9 ± 7.8 days, P = 0.001) compared to the pre-video group. The visual analogue scale for satisfaction (7.84 ± 1.62 vs. 7.68 ± 1.85 points) and mHHS (89.59 ± 9.47 vs. 89.58 ± 8.59) were similar. Conclusion: Online video instruction is an effective tool to expedite ambulation and reduce the hospital stay without compromising the clinical outcome and postoperative complications after THA.
Anxiolytic Effect of a Combination of Green Tea Extract and L-theanine
Won Kyung Lee,Tae Il Kim,Sang-ki Park,Hyoung Kook Park,Jin Tae Hong 한국실험동물학회 2010 Laboratory Animal Research Vol.26 No.1
The purpose of this study is to investigate whether the combination of green tea extract (GTE) and Ltheanine has an anxiolytic effect by oral administration through behavioral tests and neurtransmitters (or hormone) anaylses. Four week oral administration of GTE (24 ㎎/㎏), L-theanine (4 ㎎/㎏) or their combination showed anxiety-reducing effects determined by increasing numbers of head-dips in a hole board test and reducing retention time in a rota-rod test without changing spontaneous locomotor activity. Biochemical analyses indicated that the test materials decreased dopamine (DA), noradrenaline (NA), corticosterone (CS) and increased serotonin (5-HT) levels in brain cortex, hippocampus, and striatum, which suggests a possible mechanism of previous behavioral tests. Although the synergistic effects of GTE and L-theanine combination were not observed on the behavioral test, its effects on neurotransmitters (NA, CS) were synergistic and comparable to diazepam (2 ㎎/㎏ i.p.) with much less muscle relaxation side effect. Therefore, a combination of GTE and L-theanine may be useful as a functional food ingredient having an anxiolytic effect.
Hong, Soon Jun,Jeong, Han Saem,Ahn, Jeong Cheon,Cha, Dong-Hun,Won, Kyung Heon,Kim, Weon,Cho, Sang Kyoon,Kim, Seok-Yeon,Yoo, Byung-Su,Sung, Ki Chul,Rha, Seung-Woon,Shin, Joon-Han,Han, Kyoo Rok,Chung, W Elsevier 2018 Clinical therapeutics Vol.40 No.2
<P><B>Abstract</B></P> <P><B>Purpose</B></P> <P>Combination therapy with ezetimibe and statins is recommended in cases of statin intolerance or insufficiency. The objective of this study was to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus those of rosuvastatin monotherapy in patients with hypercholesterolemia.</P> <P><B>Methods</B></P> <P>I-ROSETTE (Ildong ROSuvastatin & ezETimibe for hypercholesTElolemia) was an 8-week, double-blind, multicenter, Phase III randomized controlled trial conducted at 20 hospitals in the Republic of Korea. Patients with hypercholesterolemia who required medical treatment according to National Cholesterol Education Program Adult Treatment Panel III guidelines were eligible for participation in the study. Patients were randomly assigned to receive ezetimibe 10 mg/rosuvastatin 20 mg, ezetimibe 10 mg/rosuvastatin 10 mg, ezetimibe 10 mg/rosuvastatin 5 mg, rosuvastatin 20 mg, rosuvastatin 10 mg, or rosuvastatin 5 mg in a 1:1:1:1:1:1 ratio. The primary end point was the difference in the mean percent change from baseline in LDL-C level after 8 weeks of treatment between the ezetimibe/rosuvastatin and rosuvastatin treatment groups. All patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs.</P> <P><B>Findings</B></P> <P>Of 396 patients, 389 with efficacy data were analyzed. Baseline characteristics among 6 groups were similar. After 8 weeks of double-blind treatment, the percent changes in adjusted mean LDL-C levels at week 8 compared with baseline values were –57.0% (2.1%) and –44.4% (2.1%) in the total ezetimibe/rosuvastatin and total rosuvastatin groups, respectively (<I>P</I> < 0.001). The LDL-C–lowering efficacy of each of the ezetimibe/rosuvastatin combinations was superior to that of each of the respective doses of rosuvastatin. The mean percent change in LDL-C level in all ezetimibe/rosuvastatin combination groups was >50%. The number of patients who achieved target LDL-C levels at week 8 was significantly greater in the ezetimibe/rosuvastatin group (180 [92.3%] of 195 patients) than in the rosuvastatin monotherapy group (155 [79.9%] of 194 patients) (<I>P</I> < 0.001). There were no significant differences in the incidence of overall AEs, adverse drug reactions, and serious AEs; laboratory findings, including liver function test results and creatinine kinase levels, were comparable between groups.</P> <P><B>Implications</B></P> <P>Fixed-dose combinations of ezetimibe/rosuvastatin significantly improved lipid profiles in patients with hypercholesterolemia compared with rosuvastatin monotherapy. All groups treated with rosuvastatin and ezetimibe reported a decrease in mean LDL-C level >50%. The safety and tolerability of ezetimibe/rosuvastatin therapy were comparable with those of rosuvastatin monotherapy. ClinicalTrials.gov identifier: NCT02749994.</P>
HONG, CHI-YHOU,JANG, KI-SANG,PARK, KYUNG-WON 동국대학교 자연과학연구원 1996 자연과학연구 논문집 Vol.1 No.-
Magnetic hysteresis curve and Barkhausen noise were investigated to study the change of the magnetic properties of SA 508 class 3 of nuclear pressure vessel specimen by neutron irradiation. The experiment have been performed with the as-received condition and the specimens were exposed to neutron irradiation levels of ??, ??, ??, ??, ??/㎠ (E>1Mev). The irradiation temperature was 70℃. The change of magnetic properties was observed at the above of ??/㎠. The effective magnetic saturation points were increased and Barkhausen noise were decreased according to the increasement of neutron irradiation. The change of Magnetic hysteresis curve and Barkhausen noise can be explained from the interactions of the change of domain well and misconstructive by dislocations and vacancies.
The Protective Effect of ENA Actimineral Resource A on CCl4-Induced Liver Injury in Rats
Hong, Il-Hwa,Ji, Hoon,Hwa, Sung-Yong,Jeong, Won-Il,Jeong, Da-Hee,Do, Sun-Hee,Kim, Ji-Min,Ki, Mi-Ran,Park, Jin-Kyu,Goo, Moon-Jung,Hwang, Ok-Kyung,Hong, Kyung-Sook,Han, Jung-Youn,Chung, Hae-Young,Jeong, Springer-Verlag 2011 Marine biotechnology Vol.13 No.3